Key Takeaways MRK shares jumped 32% in three months, yet the stock is still viewed as a sell.Keytruda drives over half of Merck's pharma sales, but faces 2028 patent expiry and rising competition.Merck's Gardasil sales fell 40% amid China weakness, while earnings estimates slid on recent M&A costs.Merck’s (MRK) stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained bullish momentum. ...